18
FEATURE:
A
DEPARTMENTS
J&J;/JANSSEN
6
8
10
Bill Hait, M.D., Ph.D., global head of Janssen R&D;, explains
some of the company's approaches to drug discovery which
have resulted in J&J; recently being ranked by Forbes as the
most productive drug firm in the last 10 years.
13
14
16
32
34
July 2013
CONTENTS
Welcome to
Life Science Leader
38
40
44
24
28
42
46
SPECIALTY PHARMA
STRATEGIES
BIOSIMILARS IN
EMERGING MARKETS
EXECUTIVE
COMPENSATION
48
Learn the status of biosimilar market
growth in five countries.
New changes for rewarding pharma
and bio executives
How Aptalis uses the principles of
mindset, mission, and model to guide
the company to success
BRAND
49
50
Editor's Note
Editorial Board/Ask The Board
Capitol Perspectives
Entitlement Reform
Companies To Watch
Outsourcing Insights
Prefilled Syringes
Bio Innovation Notes
Innovation In Bioprocessing
Biopharm Dev. & Manufacturing
Generic Drugs Drought
Biopharm Dev. & Manufacturing
Perils Of Building A Biotech In KY
Global Business Update
Norwegian Biotech
Pharma Management
Shifting Recruitment Patterns
Pharma Manufacturing
Update On Serialization
Contract Sourcing
GDUFA Insights
Industry Leader
Reformulating Drugs
Industry Leader
Electronic Source Records
Leadership Lessons
Importance Of Succession Planning
Follow LSL on:
@RFWrightLSL
linkedin.com/in/robertfwright
pintrest.com/rfwrightlsl
4
LifeScienceLeader.com
July 2013
